Despite being a first-line treatment for CHE, nearly 40% of patients treated with TCS had inadequate treatment response or contraindications to TCS.
9 Akershus University Hospital, Department of Obstetrics and Gynecology, Lørenskog, Norway Objective To establish expert consensus on prescreening and contraindications to moderate-to-vigorous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results